Oragenics, Inc. (OGEN) Stock Price & Analysis
Oragenics, Inc. (OGEN) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.172 (-8.99%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Oragenics, Inc. · OGEN · AMEX
Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and vaccines to combat infectious diseases. Their pipeline includes vaccine candidates targeting coronaviruses and treatments for dental caries and weight loss.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Oragenics (OGEN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality and a fragile balance sheet, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Flat; Momentum: Slipping.
- EPS beat 7 of the last 8 reports
Holding back: weak fundamentals, balance-sheet strain, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 30 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.172 |
| Change on the day | -8.99% |
| Price / earnings (trailing) | -0.32 |
| Shares traded on the day | 337.5K |
Price & events
Other perspectives
Council score for Oragenics (OGEN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Oragenics (OGEN), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Oragenics, Inc. (OGEN) is listed on AMEX. It employs 3 people.
What do the latest results show for Oragenics (OGEN)?
Short answer · as of
Against analyst estimates the company has EPS beat 7 of the last 8 reports.
What are the financial strengths and risks for Oragenics (OGEN)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 3.02.
Data-derived red flags
- Listing risk — at $0.172 the shares sit below the $1.00 minimum bid AMEX requires for continued listing.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Oragenics (OGEN)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -0.69 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for OGEN.
Checked against the records this page reads, on the dates shown above.
How does Oragenics compare with its peers?
Short answer
Oragenics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Oragenics (OGEN) — this page | $0.172 | — | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-0.69
Measured against a quoted price of $0.172 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 3
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held OGEN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported OGEN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Oragenics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the OGEN research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for OGEN?
OGEN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Oragenics, Inc. is a biotechnology company focused on developing novel antibiotics and vaccines to combat infectious diseases.
Is OGEN a good stock to buy?
Stock Expert AI does not rate OGEN buy, sell or hold. Oragenics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the OGEN stock price today?
The last price recorded for Oragenics, Inc. (OGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for OGEN?
Oragenics faces several key risks inherent to the biotechnology industry. Clinical trial failures for its vaccine and antibiotic candidates represent a significant risk, as these programs are critical to the company's future success.
What are the key factors to evaluate for OGEN?
Oragenics, Inc. (OGEN) holds a MoonshotScore in the low range. Oragenics has a license agreement with Noachis Terra Inc. for coronavirus spike protein technology. Not financial advice.
How frequently does OGEN data refresh on this page?
OGEN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven OGEN's recent stock price performance?
Oragenics, Inc. (OGEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine and antibiotic development programs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OGEN overvalued or undervalued right now?
Oragenics, Inc. (OGEN) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OGEN before investing?
Before investing in Oragenics, Inc. (OGEN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com